Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance

Abeona Therapeutics IncTrade
Tencent Music Entertainment Group - ADRTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Tencent Music Entertainment Group - ADR — how do they compare? Abeona Therapeutics Inc trades at $7.37 (market cap $421.19M), while Tencent Music Entertainment Group - ADR trades at $8.42 (market cap $16.09B). The key difference: Tencent Music Entertainment Group - ADR is far larger — about 38.2× Abeona Therapeutics Inc's market cap, and Tencent Music Entertainment Group - ADR pays a 2.75% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOTME
Market Cap
$421.19M$16.09B
Sector
HealthMedia
52-Week High
$7.45$26.36
52-Week Low
$4.17$8.16
Enterprise Value
$276.10M$14.05B
Dividend Yield
2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Tencent Music Entertainment Group - ADR

Tencent Music Entertainment (TME) is trading at $8.38, down 15.35% amid mixed Q2 2026 results that showed revenue growth but profit beat expectations. The stock faces bearish technical signals with oversold RSI conditions, while fundamentals remain strong with 33.6% net margin and attractive valuation at 10.29 P/E. Recent news highlights slowing operational growth and competitive pressures, though institutional activity shows mixed positioning with some funds increasing stakes while others reduce exposure.

TME presents a value opportunity with solid profitability and cash flow generation, but near-term headwinds include intensifying competition, AI-related copyright challenges, and slowing user growth. Analyst consensus leans neutral with 45.8% buy ratings, suggesting cautious optimism for long-term investors willing to navigate current volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Tencent Music Entertainment Group - ADR

TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.

Read more on TME